BIM
PVLA

BlackRock Investment Management’s Palvella Therapeutics PVLA Stock Holding History

BlackRock Investment Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$8K Hold
71
– – ﹤0.01% 3673
2016
Q3 		$10K Buy
71
+6
+9% +$797 ﹤0.01% 3597
2016
Q2 		$8K Buy
+65
New +$9.96K ﹤0.01% 3728

Other funds holding PVLA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Investment Management's PVLA Position: Q4 2016 in Review

BlackRock Investment Management held its Palvella Therapeutics (PVLA) position steady in Q4 2016 at 71 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #3673.

BlackRock Investment Management first reported a position in PVLA in Q2 2016 and has held it in 3 quarters since. The position peaked at $10K in Q3 2016. 24 funds tracked by Wall St. Rank hold PVLA as of Q4 2016.

  • BlackRock Investment Management held 71 shares of Palvella Therapeutics worth $8K as of Q4 2016.
  • BlackRock Investment Management left its Palvella Therapeutics share count unchanged in Q4 2016.
  • Palvella Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3673 holding.
  • BlackRock Investment Management first reported a position in Palvella Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Investment Management's Palvella Therapeutics position peaked at $10K in Q3 2016.
  • 24 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.